Abstract
Efficacy and safety of the polypeptide drug «Vesusten» in the correction of neurogenic LUTS in Multiple Sclerosis. Results of the pilot study
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
